Casey Woodring

“I guess I wanted to just ask one on the China business and how you're thinking about the outlook kind of longer term. I mean, you know, from the standpoint of value unlock and, you know, kind of a normalized growth profile, would selling that asset kind of and using that cash to pay down debt be, I guess, on the table?”

“Maybe just to follow up on some of the comments around MedDevice, you said that, you know, the softness started at some point in 3Q. Can we just get a sense of, you know, when in the quarter you started to see that?”

“I guess my first one, on the strong VWR performance here, you said half the growth was driven by commercial initiatives. Maybe can you just elaborate on that? How much of the VWR beat was driven by previously disclosed large contract wins versus some of the other commercial initiatives you have going on?”

“I just wanted to clarify the 27 comments you made earlier. I guess, what's the implied organic growth rate you're assuming, or maybe you asked another way, what do you expect as far as M&A contribution from BioLife in 27?”

“Please go ahead. great thank you for taking my questions and julie uh looking forward to working with you uh maybe a follow-up to an earlier question but just on massimo you talked a little bit about how you view the business fitting into danaher and you obviously led that deal as head of diagnostics but maybe can you…”